This is a phase 1, randomized, double-blind, placebo-controlled, multiple ascending dose study. Twenty-four subjects with Rheumatoid Arthritis will be selected to participate. Subjects will be randomized to receive either ABT-122 or placebo. ABT-122 or placebo will be administered as subcutaneous (under the skin) injections in three dosing groups.
Read more: http://www.clinicaltrials.gov/ct2/show/NCT01853033?cond=%22Arthritis%22&lup_s=08/23/2013&lup_d=30
